Abivax Announces its Ordinary and Extraordinary General Meet

PARIS, FRANCE / ACCESSWIRE / May 15, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system

Related Keywords

France , United States , Paris , France General , French , Anne Hennecke , Enregistrement Universel , Jeanene Timberlake , Ligia Vela Reid , Regina Jehle , Ghislaine Gasparetto , Rooney Partners , Relations Investors Europe , Dechert Paris , Mc Services , Euronext , Euronext Paris , Shareholder Meeting , Truffle Capital , French Autorit , Des March , Gefallene Big Techs , Abivax , Nnounces , Rdinary , Xtraordinary , Eneral , Meeting , Pune , 023 , Availability , Preparatory , Documents ,